RU2008112202A - Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств - Google Patents
Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств Download PDFInfo
- Publication number
- RU2008112202A RU2008112202A RU2008112202/04A RU2008112202A RU2008112202A RU 2008112202 A RU2008112202 A RU 2008112202A RU 2008112202/04 A RU2008112202/04 A RU 2008112202/04A RU 2008112202 A RU2008112202 A RU 2008112202A RU 2008112202 A RU2008112202 A RU 2008112202A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkylene
- mono
- compounds
- unsubstituted
- Prior art date
Links
- -1 PHENYL GROUP Chemical group 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 31
- 125000000217 alkyl group Chemical group 0.000 claims abstract 25
- 125000002947 alkylene group Chemical group 0.000 claims abstract 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 22
- 229910052736 halogen Inorganic materials 0.000 claims abstract 16
- 125000003118 aryl group Chemical group 0.000 claims abstract 15
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 15
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 15
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 15
- 150000002367 halogens Chemical class 0.000 claims abstract 13
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 10
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 10
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 6
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims abstract 6
- 125000004450 alkenylene group Chemical group 0.000 claims abstract 6
- 125000004429 atom Chemical group 0.000 claims abstract 6
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims abstract 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract 3
- 125000001118 alkylidene group Chemical group 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021235 | 2005-09-29 | ||
| EP05021235.6 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008112202A true RU2008112202A (ru) | 2009-10-10 |
Family
ID=35809809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008112202/04A RU2008112202A (ru) | 2005-09-29 | 2006-09-26 | Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств |
| RU2008112201/04A RU2008112201A (ru) | 2005-09-29 | 2006-09-26 | Производные фенил- и пиридил-1, 2, 4-оксадиазолона с фенильной группой, способы их получения и их применение в качестве фармацевтических средств |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008112201/04A RU2008112201A (ru) | 2005-09-29 | 2006-09-26 | Производные фенил- и пиридил-1, 2, 4-оксадиазолона с фенильной группой, способы их получения и их применение в качестве фармацевтических средств |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20080287409A1 (enExample) |
| EP (2) | EP1931660B1 (enExample) |
| JP (2) | JP5183479B2 (enExample) |
| KR (2) | KR20080048520A (enExample) |
| CN (2) | CN101268069A (enExample) |
| AR (2) | AR056203A1 (enExample) |
| AT (1) | ATE537167T1 (enExample) |
| AU (2) | AU2006299086A1 (enExample) |
| BR (2) | BRPI0616465A2 (enExample) |
| CA (2) | CA2624093A1 (enExample) |
| CR (1) | CR9784A (enExample) |
| CY (1) | CY1113376T1 (enExample) |
| DK (1) | DK1931660T3 (enExample) |
| DO (2) | DOP2006000205A (enExample) |
| EC (1) | ECSP088323A (enExample) |
| ES (1) | ES2392181T3 (enExample) |
| IL (2) | IL190228A0 (enExample) |
| MA (2) | MA29807B1 (enExample) |
| MY (2) | MY149182A (enExample) |
| NO (2) | NO20081370L (enExample) |
| NZ (2) | NZ566878A (enExample) |
| PE (2) | PE20070545A1 (enExample) |
| PL (1) | PL1931660T3 (enExample) |
| PT (1) | PT1931660E (enExample) |
| RU (2) | RU2008112202A (enExample) |
| SI (1) | SI1931660T1 (enExample) |
| TN (1) | TNSN08145A1 (enExample) |
| TW (2) | TW200811154A (enExample) |
| UY (2) | UY29829A1 (enExample) |
| WO (2) | WO2007039172A1 (enExample) |
| ZA (1) | ZA200801630B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| CA2666219C (en) | 2006-10-16 | 2017-02-07 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US10793515B2 (en) * | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US20210130285A1 (en) * | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1200824A1 (en) * | 2012-01-18 | 2015-08-14 | Daiichi Sankyo Company, Limited | Substituted phenylazole derivative |
| JP2015525223A (ja) | 2012-06-14 | 2015-09-03 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体を使用する有害生物防除方法 |
| US10258672B2 (en) | 2014-10-09 | 2019-04-16 | Case Western Reserve University | Compositions and methods of treating root avulsion injury |
| CN106616029B (zh) * | 2016-12-08 | 2020-05-01 | 西南大学 | 一种提高虹鳟抗病能力的饲料添加剂及其制备方法 |
| CN108976150B (zh) * | 2017-06-05 | 2022-11-18 | 重庆博腾制药科技股份有限公司 | 一种3-乙基-4-氟苯腈的制备方法 |
| WO2019014342A1 (en) * | 2017-07-11 | 2019-01-17 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES |
| US20220387393A1 (en) * | 2019-11-06 | 2022-12-08 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2025237291A1 (zh) * | 2024-05-13 | 2025-11-20 | 上海翰森生物医药科技有限公司 | 一种异丙基异喹啉类化合物的制备方法及其中间体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| JP2000511883A (ja) | 1996-04-19 | 2000-09-12 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| WO2000078313A1 (en) * | 1999-06-18 | 2000-12-28 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| IL160304A0 (en) * | 2001-08-10 | 2004-07-25 | Nippon Chemiphar Co | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta |
| DE60315603T2 (de) * | 2002-02-25 | 2008-05-21 | Eli Lilly And Co., Indianapolis | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
| WO2004080943A1 (ja) | 2003-03-11 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| EP1690538A4 (en) | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| KR20060135854A (ko) * | 2004-04-01 | 2006-12-29 | 아벤티스 파마슈티칼스 인크. | Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온 |
-
2006
- 2006-09-26 NZ NZ566878A patent/NZ566878A/en not_active IP Right Cessation
- 2006-09-26 BR BRPI0616465-0A patent/BRPI0616465A2/pt not_active Application Discontinuation
- 2006-09-26 RU RU2008112202/04A patent/RU2008112202A/ru not_active Application Discontinuation
- 2006-09-26 JP JP2008532648A patent/JP5183479B2/ja not_active Expired - Fee Related
- 2006-09-26 PL PL06792252T patent/PL1931660T3/pl unknown
- 2006-09-26 RU RU2008112201/04A patent/RU2008112201A/ru not_active Application Discontinuation
- 2006-09-26 ES ES06792252T patent/ES2392181T3/es active Active
- 2006-09-26 WO PCT/EP2006/009298 patent/WO2007039172A1/en not_active Ceased
- 2006-09-26 SI SI200631453T patent/SI1931660T1/sl unknown
- 2006-09-26 WO PCT/EP2006/009304 patent/WO2007039178A2/en not_active Ceased
- 2006-09-26 DK DK06792252.6T patent/DK1931660T3/da active
- 2006-09-26 KR KR1020087007735A patent/KR20080048520A/ko not_active Withdrawn
- 2006-09-26 EP EP06792252A patent/EP1931660B1/en active Active
- 2006-09-26 CN CNA2006800344489A patent/CN101268069A/zh active Pending
- 2006-09-26 JP JP2008532645A patent/JP2009509986A/ja not_active Abandoned
- 2006-09-26 CA CA002624093A patent/CA2624093A1/en not_active Abandoned
- 2006-09-26 CN CNA2006800359450A patent/CN101273036A/zh active Pending
- 2006-09-26 NZ NZ566875A patent/NZ566875A/en not_active IP Right Cessation
- 2006-09-26 AU AU2006299086A patent/AU2006299086A1/en not_active Abandoned
- 2006-09-26 BR BRPI0616457-9A patent/BRPI0616457A2/pt not_active IP Right Cessation
- 2006-09-26 AT AT06805857T patent/ATE537167T1/de active
- 2006-09-26 PT PT06792252T patent/PT1931660E/pt unknown
- 2006-09-26 CA CA2624105A patent/CA2624105C/en not_active Expired - Fee Related
- 2006-09-26 EP EP06805857A patent/EP1934206B1/en active Active
- 2006-09-26 AU AU2006299092A patent/AU2006299092A1/en not_active Abandoned
- 2006-09-27 DO DO2006000205A patent/DOP2006000205A/es unknown
- 2006-09-27 TW TW095135657A patent/TW200811154A/zh unknown
- 2006-09-27 MY MYPI20064223A patent/MY149182A/en unknown
- 2006-09-27 AR ARP060104225A patent/AR056203A1/es not_active Application Discontinuation
- 2006-09-27 DO DO2006000204A patent/DOP2006000204A/es unknown
- 2006-09-27 AR ARP060104222A patent/AR056541A1/es not_active Application Discontinuation
- 2006-09-27 TW TW095135660A patent/TWI398436B/zh not_active IP Right Cessation
- 2006-09-27 MY MYPI20064224A patent/MY148982A/en unknown
- 2006-09-28 PE PE2006001178A patent/PE20070545A1/es not_active Application Discontinuation
- 2006-09-29 PE PE2006001189A patent/PE20070768A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29829A patent/UY29829A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29830A patent/UY29830A1/es not_active Application Discontinuation
-
2008
- 2008-02-19 ZA ZA2008/01630A patent/ZA200801630B/en unknown
- 2008-02-29 CR CR9784A patent/CR9784A/es not_active Application Discontinuation
- 2008-03-14 NO NO20081370A patent/NO20081370L/no not_active Application Discontinuation
- 2008-03-14 NO NO20081367A patent/NO20081367L/no not_active Application Discontinuation
- 2008-03-17 IL IL190228A patent/IL190228A0/en unknown
- 2008-03-17 IL IL190227A patent/IL190227A/en not_active IP Right Cessation
- 2008-03-24 MA MA30783A patent/MA29807B1/fr unknown
- 2008-03-24 MA MA30780A patent/MA29804B1/fr unknown
- 2008-03-25 KR KR1020087007148A patent/KR101342415B1/ko not_active Expired - Fee Related
- 2008-03-26 US US12/055,793 patent/US20080287409A1/en not_active Abandoned
- 2008-03-26 US US12/055,764 patent/US7834030B2/en not_active Expired - Fee Related
- 2008-03-27 EC EC2008008323A patent/ECSP088323A/es unknown
- 2008-03-28 TN TNP2008000145A patent/TNSN08145A1/en unknown
-
2009
- 2009-05-29 US US12/474,838 patent/US7851493B2/en not_active Expired - Fee Related
-
2012
- 2012-10-31 CY CY20121101040T patent/CY1113376T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008112202A (ru) | Производные фенил-[1,2,4]-оксадиазол-5-она с фенильной группой, способы их получения и их применение в качестве фармацевтических средств | |
| RU2010154279A (ru) | Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| RU2015100901A (ru) | Производные эфира гетероарилкарбоновой кислоты | |
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| JP2004504388A5 (enExample) | ||
| RU2008112198A (ru) | Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств | |
| CA2653034A1 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| HUP0301427A2 (hu) | Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR045651A1 (es) | Derivados de tiazol como moduladores del receptor de cannabinoide | |
| CA2394086A1 (fr) | Derives de 4-aminopiperidine et leur utilisation en tant que medicament | |
| RU2008116581A (ru) | Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| RU2010107169A (ru) | Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого | |
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| ATE487474T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| JP2008512408A5 (enExample) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| RU2013118021A (ru) | Способы и композиции для лечения сахарного диабета и дислипидемии | |
| BRPI0708596A2 (pt) | composto de rutênio, composição, uso de um composto, e, método de tratamento de um indivìduo que sofre de cáncer | |
| RU2004133387A (ru) | Фармацевтический препарат с немедленным высвобождением | |
| RU2008113211A (ru) | N-[1, 3,4]-тиадиазол-2-илбензолсульфонамиды, способы их получения и их применение в качестве лекарственных средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100803 |